Drilldown: Medicines

2-FA (1) · 2-FMA (1) · 3-FA (1) · 3-FMA (1) · 4-FA (1) · 4-FMA (1) · Butorphanol (1) · Codeine (2) · Dextroamphetamine (1) · Dextropropoxyphene (1) · Dihydrocodeine (1) · Ethylmorphine (1) · Fenethylline (1) · Fentanyl (1) · Hydrocodone (1) · Hydromorphone (1) · Levorphanol (1) · Meperidine (1) · Methamphetamine (1) · Mixed amphetamine salts (1) · Nalbuphine (1) · Oxymorphone (1) · Papaverine (1) · Pentazocine (1) · Tapentadol (1)

None (11) · (multiple, generic dominant) (1) · Adderall, Adderall XR, Mydayis (1) · Captagon (1) · Darvon (1) · Demerol (1) · Desoxyn (1) · Dexedrine (1) · Dilaudid (1) · Duragesic (1) · Nubain (1) · Nucynta (1) · Opana (1) · Stadol (1) · Talwin (1) · Vicodin (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antiparkinsonian · Antipsychotic · Empathogen · Neuroleptic · Cathinone

Other values:

Search

Kappa agonist; mu antagonist (1) · Kappa agonist; mu partial agonist (1) · Kappa agonist; mu partial agonist/antagonist (1) · Monoamine releasing agent (6) · Monoamine releasing agent, TAAR1 agonism, VMAT2 substrate, DAT/NET reverse transport (1) · Monoamine releasing agent; serotonergic at higher doses (1) · Mu-opioid agonist; norepinephrine reuptake inhibitor (1) · Mu-opioid receptor agonist (4) · Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Mu-opioid receptor agonist; sodium channel blocker (1) · Mu/kappa/delta agonist; NMDA antagonist (1) · Phosphodiesterase inhibitor; calcium channel blocker (1) · Potent mu-opioid receptor agonist (3) · Prodrug of amphetamine + theophylline (1) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) · TAAR1 agonism, VMAT2 substrate, DAT/NET reverse transport, net release of dopamine and norepinephrine (1)

None (23) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-000004B9-QINU`"', '"`UNIQ--vote-000004BA-QINU`"', '"`UNIQ--vote-000004BB-QINU`"' (1) · '"`UNIQ--vote-00000562-QINU`"', '"`UNIQ--vote-00000563-QINU`"', '"`UNIQ--vote-00000564-QINU`"', '"`UNIQ--vote-00000565-QINU`"', '"`UNIQ--vote-00000566-QINU`"' (1)

None (23) · 2.5 mg IR, 5 mg XR, or 12.5mg Mydayis (1) · 5 mg PO (1) · Adult: 15–60 mg every 4 hours as needed. (1)

None (23) · Desoxyn 5 mg tabs (1) · IR tabs 5, 7.5, 10, 12.5, 15, 20, 30 mg; XR caps 5, 10, 15, 20, 25, 30 mg; Mydayis caps 12.5, 25, 37.5, 50 mg (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (23) · 25 mg/day (ADHD per Desoxyn label); 15 mg/day (obesity, short-term, per Desoxyn label) (1) · 360 mg/day (1) · XR = 40 or 60 mg/d; IR = 40 or 60 mg/d'"`UNIQ--ref-00000567-QINU`"' (1)

None (23) · Oral (1) · Oral (prescribed) (1) · PO (only formulation marketed in the US). (1)

None (24) · 30–60 min (PO) (1) · IR: 30–60 min; XR: 1–2 h to peak effect (1)

None (24) · 4–6 hours (1) · IR 4–6 h; XR 10–12 h; Mydayis 14–16 h (1)

None (24) · 2.5–3 hours (1) · D-amphetamine ~10 h; L-amphetamine ~13 h (adults) (1)

None (24) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1) · ~75–90% (oral) (1)

None (23) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Category C (1) · Category C (per Desoxyn label) (1)

None (23) · Schedule II (2) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1)